Treatment of community-acquired pneumonia

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 12, 2008, Pages 1245-1246

  Low, Donald E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BRONCHIOLITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; HOSPITAL ADMISSION; HUMAN; NOTE;

EID: 57349190336     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.081593     Document Type: Note

References (10)

1. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008;179:1269-77.
2. British Thoracic Society of Standards of Care Committee (BTS). BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56(Suppl 4):1-64.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
4. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-93.
5. Oosterheert JJ, Bonten MJ, Hak E, et al. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 2003;52:555-63.
6. Oishi K, Sonoda F, Kobayashi S, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994;62:4145-52.
7. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect 2002;8(Suppl 2):1-11.
8. Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006;43:432-8.
9. Daneman N, Low DE, McGeer A, et al. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis 2008;46:1131-8.
10. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005;40:1288-97.